Cutaneous Toxicities from Anti-Cancer Therapies 1

These dermatologic reactions follow recognizable patterns and are closely related to the type of treatment given.

What is the content of "Cutaneous Toxicities from Anti-Cancer Therapies" ?

Cutaneous Toxicities from Anti-Cancer Therapies,by Drs. Allireza Alloo and Nicole LeBoeuf, provides comprehensive coverage of cutaneous toxicities caused by the full spectrum of oncologic modes of treatment—specifically cytotoxic chemotherapy, targeted chemotherapy, and immunotherapy.

This portable photoguide is a quick bedside handbook for dermatologists, oncologists, primary care providers, emergency room physicians, and other health care professionals who see patients undergoing treatment for cancer.

• Summarizes current evidence on skin toxicity from oncologic treatment using a succinct, highly practical format for quick reference

• Defines specific reaction patterns for oncology therapies and provides clinical pearls and treatment recommendations

• Features abundant full-color clinical photos that help you quickly identify reaction patterns and skin toxicity from specific cancer therapies

• Highlights special considerations for skin of color and pediatrics in boxes throughout the book
   

  Enrich Your eBook Reading Experience

• Read directly on your preferred device(s),such as computer, tablet, or smartphone.

• Easily convert to audiobook,powering your content with natural language text-to-speech.

Who are the authors of "Cutaneous Toxicities from Anti-Cancer Therapies" ?

Dr. Allireza Alloo is an Assistant Professor of Dermatology at the Hofstra Northwell School of Medicine and is board certified in dermatology by the American Board of Dermatology. He is also the Director of the Program in Cutaneous Chemotoxicties at Northwell/R.J. Zuckerberg Cancer Center.

Dr. Alloo's clinical and research interests include complex medical dermatology, inpatient dermatology, autoimmune blistering diseases, and cutaneous toxicities to chemotherapy. Dr. Alloo is a member of several dermatology organizations including the American Academy of Dermatology, the Society of Dermatology Hospitalists, and the Medical Dermatology Society.

Dr. Alloo has served as an ad-hoc reviewer for multiple prominent dermatology journals, including JAMA Dermatology and the Journal of the American Academy of Dermatology. He has also published numerous articles in peer-reviewed literature, authored several book chapters, as well as given talks at local, regional, and national dermatology conferences.

Nicole R. LeBoeuf, MD, MPH, FAAD : Vice Chair, Department of Dermatology, Dana-Farber Brigham Cancer Center, Division Chief of Oncodermatology, Dana-Farber Brigham Cancer Center, Director, Center for Cutaneous Oncology, Dana-Farber Brigham Cancer Center , Director, The Program in Skin Toxicities from Anticancer Therapies, Director, Cutaneous Oncology Fellowship Program, Co-Director, Complex Medical Dermatology Fellowship Program, Associate Professor, Harvard Medical School, Boston, MA, USA